FDA Approves Fam-Trastuzumab Deruxtecan-Nxki for Metastatic …
Dec 15, 2025 · The FDA approved trastuzumab deruxtecan plus pertuzumab for first-line HER2-positive metastatic breast cancer after DESTINY-Breast09 showed major PFS gains.
FDA approves fam-trastuzumab deruxtecan-nxki with pertuzumab for ...
Dec 15, 2025 · Efficacy was evaluated in DESTINY-Breast09 (NCT04784715), a randomized, three-arm, multicenter, global trial that enrolled 1157 adults with HER2-positive advanced or metastatic breast …
FDA Approves T-DXd With Pertuzumab for First-Line Treatment of Advanced …
Dec 15, 2025 · Key Takeaways FDA approved T-DXd with pertuzumab for first-line treatment of HER2-positive metastatic breast cancer, supported by DESTINY-Breast09 trial results. DESTINY-Breast09 …
What's next for metastatic breast cancer treatments? | LBBC
Dec 16, 2025 · Researchers gave insight into drugs that are being studied for use in metastatic breast cancer when the first treatment stops working.
New FDA Approved Drug Combo Offers Hope For Patients
Dec 18, 2025 · Understanding HER+ Breast Cancer A new FDA-approved treatment for HER2-positive metastatic breast cancer—trastuzumab deruxtecan (Enhertu) in combination with pertuzumab …
Enhertu Plus Pertuzumab Approved for First-Line HER2+ Breast Cancer
6 days ago · The FDA approved Enhertu with pertuzumab for the first-line treatment of adults with unresectable or metastatic HER2-positive breast cancer.
Treatment of Stage IV (Metastatic) Breast Cancer
Treatment of Stage IV (Metastatic) Breast Cancer Stage IV cancers have spread (metastasized) beyond the breast and nearby lymph nodes to other parts of the body. When breast cancer spreads, it most …
DESTINY-Breast09: Trastuzumab Deruxtecan Plus Pertuzumab Sets …
Jun 2, 2025 · DESTINY-Breast09 is the first trial in more than a decade to demonstrate a clinically meaningful improvement in outcomes for a broad group of patients with HER2-positive metastatic …
FDA Fast Tracks Emiltatug Ledadotin in Advanced/Metastatic Breast Cancer
Jan 13, 2025 · The FDA has granted a new fast track designation to emiltatug ledadotin for the treatment of advanced or metastatic breast cancer, specifically targeting patients with HER2-low or …
AstraZeneca, Daiichi's breast cancer drug gets FDA nod as first ... - MSN
The approval is based on the results from a study that enrolled 1,157 patients with advanced HER2-positive breast cancer who had not received prior chemotherapy for metastatic disease.